Kiniksa Pharmaceuticals, Ltd. (KNSA) financial statements and ratios from SEC XBRL: revenue $0.8B (TTM), net margin 8.7%, revenue growth 55.5% YoY, P/E 90.1. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $677.56M |
| Revenue (TTM) | $0.8B |
| Net Margin | 8.7% |
| Operating Margin (TTM) | 12.4% |
| Revenue Growth (YoY) | 55.5% |
| EPS Growth (YoY) | 150.0% |
| FCF Growth (YoY) | 125.1% |
| P/E Ratio | 90.1 |
| EV / EBITDA | 67.5 |
| Price / Book | 10.87 |
| Price / Sales | 8.73 |
| FCF Yield | 2.1% |
| Altman Z-Score | 20.16 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.6 |
KNSA overview · KNSA earnings · KNSA KPIs · KNSA documents · KNSA ownership · KNSA peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.